Amgen: Potential Multi-Bagger
Amgen is fast approaching 40 years in business, a great achievement for a business in a rapidly shifting and precarious sector.
Amgen is listed in US and share price last closed at USD159.15.
Since inception, the California firm has developed/acquired an array of blockbuster drugs lead by the $6 billion monster Enbrel.
For all the negative headlines over patent expirations and increased competition, 10 out of Amgen's 13 drugs increased sales in 2016.
Epogen and Neupogen are rapidly declining but both drugs have been around for over a quarter of a century.
The challenge for management is to develop the pipeline - particularly Erenumab and Amgevita - so as to maintain growth.
Amgen has generated consistent earnings growth (see below).
Chart point to big gain for Amgen (CNBC video):
video.cnbc.com/gallery/?video=3000624101
Amgen is listed in US and share price last closed at USD159.15.
Since inception, the California firm has developed/acquired an array of blockbuster drugs lead by the $6 billion monster Enbrel.
For all the negative headlines over patent expirations and increased competition, 10 out of Amgen's 13 drugs increased sales in 2016.
Epogen and Neupogen are rapidly declining but both drugs have been around for over a quarter of a century.
The challenge for management is to develop the pipeline - particularly Erenumab and Amgevita - so as to maintain growth.
Amgen has generated consistent earnings growth (see below).
Chart point to big gain for Amgen (CNBC video):
video.cnbc.com/gallery/?video=3000624101
Comments
Post a Comment